RYR2 and catecholaminergic polymorphic ventricular tachycardia: This study aimed to evaluate the safety of a nanoformulated siRNA developed to target the mutated cardiac Ryanodine Receptor gene (RyR2) that causes dominant catecholaminergic polymorphic ventricular tachycardia (CPVT).